Cassava Sciences Inc SAVA Morningstar Rating Rating as of Aug 7, 2020. other biomarker assessments. In fact, What if detecting Alzheimer’s was as simple as getting a blood test?


The average price we get from analysts is $16.00 which is -$3.4 below current price. It is unlikely that any one drug will successfully treat Alzheimer's disease.All this makes the case to consider the development of new and promising approaches for the treatment and diagnosis of Alzheimer's disease.Unraveling Alzheimer's disease is a hard problem. About Cassava Sciences, Inc. Cassava Sciences' mission is to discover and develop innovations for chronic, neurodegenerative conditions.

Our work is complex, risky, labor-intensive, persistent and expensive. effects of PTI-125 on cognition. “This effort is on-going. bioanalysis showed unnaturally high variability and other problems, The data set from that initial bioanalysis showed unnaturally high variability and other problems, such as no correlation among changes in levels of biomarkers over 28 days, even in the placebo group, and different biomarkers of disease moving in opposite directions in the same patient. prior work experience) generated an initial bioanalysis in which Over the past 10 years, Cassava Sciences has combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer's disease. This number will increase significantly in the years ahead. An outside lab (with whom the Company had no prior work experience) generated an initial bioanalysis in which the study missed its pre-specified primary outcome, defined as a drug effect on cerebrospinal fluid (CSF) levels of tau protein and other biomarker assessments.
Over 5 million people have Alzheimer's disease in the U.S. today. President & CEO. we believe data from the initial bioanalysis can be interpreted as

We translate novel scientific insights into new medicines. Currently, there are no drug therapies to halt Alzheimer's disease, much less reverse its course. - Final Clinical Results of a Phase 2b Study i n Alzheimer’s Disease with Lead Drug Candidate, PTI-125, Expected to be Announced September 2020 -  - SavaDx Demonstrates Direct Evidence of Target Engagement & Treatment Effects - - Open-label Study Of PTI-125 Reaches >50% Enrollment - AUSTIN, Texas ,AUSTIN, Texas , July 09, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq:SAVA), a biotechnology company focused on Alzheimer’s disease, today announced that its lead neuroscientist, Lindsay H. Burns , PhD, will give a keynote presentation at the Biomarkers for Alzheimer’s Disease Summit , aAUSTIN, Texas , June 16, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq:SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that the Company will be added to the Russell 2000 ® and Russell 3000 ® Indexes, effective after the close of the U.S.- High Variability in Levels of Biomarkers in Control Arm of Phase 2b Study May Drive Reassessment of Overall Study Results - - Effects Of PTI-125 on Cognition, Other Analysis and Data Expected 2 nd Half 2020 - - Updated Corporate Presentation Now Available on Website - AUSTIN, Texas , June 03,- Study Showed High Variability in Levels of CSF Biomarkers Over 28 Days - - Drug Was Safe and Well-tolerated - AUSTIN, Texas , May 15, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today reported top-line results from a Phase 2b study of PTI-125, its lead investigational drug, in- Anticipates Early Data Readout for Phase 2b Study of PTI-125 in Alzheimer’s Disease - - Approximately $2.9 Million in NIH Research Grants Awarded in 2020 - - Open-Label Study of PTI-125 Initiated in Alzheimer’s Disease - AUSTIN, Texas , May 06, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc.- Grant Will Support an On-going Clinical Evaluation of Lead Investigational Drug PTI-125 in Alzheimer’s Disease - AUSTIN, Texas , April 23, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it- Top-Line Results of a Phase 2b in Alzheimer’s On Track for Mid-Year 2020 - - Cash Balance Exceeds $26 Million at January 31, 2020 - - $5 Million Net Cash Use Expected in 2020 - AUSTIN, Texas , March 26, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc.Approximately 100 Study Participants Will Receive PTI-125 For 12 Months AUSTIN, Texas , March 25, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the initiation of an open-label extension study toAUSTIN, Texas , March 19, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced clinical updates and business progress across its pipeline of product candidates under development.

We anticipate announcing such results in 'Our Phase 2b study was well-conducted, but we believe the analysis of results is a re-do,' said Update on Open-label Study with PTI-125 - Initiated in March, Now Over 50% EnrolledNet cash used in operations during the six months ended Net cash use for full year 2020 is expected to be approximately Alzheimer's disease is a progressive brain disorder that destroys memory and thinking skills. believe the analysis of results is a re-do,” said Remi Barbier, The Company develops safer and efficacious drugs for use in pain management, particularly in …

Over the past 10 years, Cassava Sciences has combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer’s disease.

the study missed its pre-specified primary outcome, defined as a About Cassava Sciences Inc Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. A long-prevailing scientific hypothesis - clearing amyloid from the brain - has led to high-profile clinical failures.

clinical results are announced in September 2020.”For more information, please visit:

We anticipate announcing such

As previously reported, the drug was safe and well-tolerated.

With this latest performance, SAVA shares dropped by -7.95% in over the last four-week period, additionally sinking by -57.14% over the last 6 months – not to mention a rise of 173.17% in the past year of trading. Cassava Sciences owns worldwide development and …